Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
- Conditions
- Myocardial InfarctionAcute Coronary Syndrome
- Registration Number
- NCT01623700
- Lead Sponsor
- Uppsala University
- Brief Summary
This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).
The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 78000
- Patient with an event of ACS under the study period
- Patient found in the National Registry of Drug Prescriptions and treated or not treated with antithrombotic drug/s (acetylsalicylic acid and/or either clopidogrel/ticlopidine/prasugrel and/or warfarin)
- Patients will not be excluded from the database if they fulfill inclusion criteria.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method number of patients with adverse events in patient groups with different antithrombotic treatment strategies up to 5 years and 6 months adverse events such as: mortality, re-infarction, revascularization, ischemic- and non-ischemic stroke and bleeding
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University
🇸🇪Uppsala, Uppsala County, Sweden